Your session is about to expire
← Back to Search
PRMT5 Inhibitor
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Phase 1
Waitlist Available
Research Sponsored by Prelude Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through approximately 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing PRT811, a new drug, in patients with advanced cancers who have no other treatment options. PRT811 works by blocking a protein that helps cancer cells grow.
Eligible Conditions
- Solid Tumors
- Brain Tumor
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through approximately 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through approximately 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To describe dose limiting toxicities (DLT) of PRT811
To determine the maximally tolerated dose (MTD)
To determine the recommended phase 2 dose (RP2D) and schedule of PRT811
Secondary study objectives
To describe any anti-tumor activity of PRT811
To describe the adverse event profile and tolerability of PRT811
To describe the pharmacokinetic profile of PRT811
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: PRT811Experimental Treatment1 Intervention
PRT811 will be administered orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRT811
2019
Completed Phase 1
~90
Find a Location
Who is running the clinical trial?
Prelude TherapeuticsLead Sponsor
10 Previous Clinical Trials
971 Total Patients Enrolled